Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A HDL-based cirrhosis risk score improves the prediction of short-term mortality in acutely decompensated cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates neutrophilic inflammation and glucocorticoid receptor-β expression in COPD.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Phospholipase A<sub>2</sub> products influence the antiplatelet functions of synthetic high-density lipoproteins.

Journal of lipid research·2025
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Succinate in innate immunity: linking metabolic reprogramming to immune modulation.

Frontiers in immunology·2025
Same author

ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction.

Cells·2025

Related Experiment Video

Updated: May 13, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

E-type prostanoid receptor 4 (EP4) in disease and therapy.

Viktoria Konya1, Gunther Marsche, Rufina Schuligoi

  • 1Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Austria.

Pharmacology & Therapeutics
|March 26, 2013
PubMed
Summary

Prostaglandin E2 (PGE2) signals through four E-type prostanoid (EP) receptors, with EP4 emerging as a key target. This review summarizes EP4 signaling pathways and therapeutic potential for EP4 agonists and antagonists.

More Related Videos

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Related Experiment Videos

Last Updated: May 13, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with &beta;-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Prostaglandin E2 (PGE2) exerts diverse biological functions via four E-type prostanoid (EP) receptors.
  • Genetic models and selective modulators have elucidated PGE2's physiological and clinical relevance.
  • Distinct EP receptors present therapeutic opportunities in various disease models.

Purpose of the Study:

  • To review EP4 receptor-triggered signaling modules.
  • To explore therapeutic applications of EP4-selective agonists and antagonists.
  • To highlight the EP4 receptor's emerging versatility.

Main Methods:

  • Literature review of studies utilizing genetic ablation of EP receptors.
  • Analysis of research on selective EP agonists and antagonists.
  • Examination of disease models investigating EP receptor roles.

Main Results:

  • The EP4 receptor exhibits both beneficial (anti-inflammatory, anti-thrombotic, vasoprotective) and detrimental (tumor-promoting, pro-angiogenic) roles.
  • Multiple signaling pathways are activated upon EP4 receptor engagement.
  • EP4 receptor function is context-dependent, contributing to its diverse biological effects.

Conclusions:

  • The EP4 receptor is a promising target for therapeutic intervention.
  • Understanding EP4 signaling pathways is crucial for developing targeted therapies.
  • Selective EP4 agonists and antagonists hold potential for treating inflammatory, thrombotic, and oncological conditions.